Actinium Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Actinium Pharmaceuticals is Sandesh Seth, benoemd in Jun2017, heeft een ambtstermijn van 7.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.70M, bestaande uit 15% salaris en 85% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.017% van de aandelen van het bedrijf, ter waarde $ 7.91K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.2 jaar en 11 jaar.

Belangrijke informatie

Sandesh Seth

Algemeen directeur

US$4.7m

Totale compensatie

Percentage CEO-salaris	15.0%
Dienstverband CEO	7.4yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	3.2yrs
Gemiddelde ambtstermijn bestuur	11yrs

Recente managementupdates

Recent updates

Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans

Dec 28

Analyse CEO-vergoeding

Hoe is Sandesh Seth's beloning veranderd ten opzichte van Actinium Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$41m
Jun 30 2024	n/a	n/a	-US$43m
Mar 31 2024	n/a	n/a	-US$46m
Dec 31 2023	US$5m	US$705k	-US$49m
Sep 30 2023	n/a	n/a	-US$50m
Jun 30 2023	n/a	n/a	-US$46m
Mar 31 2023	n/a	n/a	-US$39m
Dec 31 2022	US$4m	US$665k	-US$33m
Sep 30 2022	n/a	n/a	-US$30m
Jun 30 2022	n/a	n/a	-US$27m
Mar 31 2022	n/a	n/a	-US$25m
Dec 31 2021	US$2m	US$615k	-US$25m
Sep 30 2021	n/a	n/a	-US$23m
Jun 30 2021	n/a	n/a	-US$22m
Mar 31 2021	n/a	n/a	-US$22m
Dec 31 2020	US$2m	US$578k	-US$22m
Sep 30 2020	n/a	n/a	-US$20m
Jun 30 2020	n/a	n/a	-US$21m
Mar 31 2020	n/a	n/a	-US$22m
Dec 31 2019	US$1m	US$561k	-US$22m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$23m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$1m	US$545k	-US$24m
Sep 30 2018	n/a	n/a	-US$22m
Jun 30 2018	n/a	n/a	-US$23m
Mar 31 2018	n/a	n/a	-US$25m
Dec 31 2017	US$306k	US$306k	-US$27m

Compensatie versus markt: De totale vergoeding ($USD 4.70M ) Sandesh } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 652.28K ).

Compensatie versus inkomsten: De vergoeding van Sandesh is gestegen terwijl het bedrijf verliesgevend is.

CEO

Sandesh Seth (60 yo)

7.4yrs

Tenure

US$4,704,999

Compensatie

Mr. Sandesh C. Seth, M.S., MBA has been Chief Executive Officer of Actinium Pharmaceuticals, Inc. since June 5, 2017. Mr. Seth serves as the Head of Healthcare Investment Banking at Laidlaw & Company (UK)...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Sandesh Seth	Chairman & CEO	7.4yrs	US$4.70m	0.017% $ 7.9k
Steven O'Loughlin	CFO & Corporate Secretary	7.5yrs	US$1.49m	0.0038% $ 1.7k
Paul Diamond	Vice President of Patent & Legal Counsel	3.2yrs	geen gegevens	geen gegevens
Avinash Desai	Chief Medical Officer	4yrs	geen gegevens	geen gegevens
Jenny Hsieh	Chief Strategy Officer	2.1yrs	geen gegevens	geen gegevens
Sunitha Lakshminarayanan	Senior VP	2.1yrs	geen gegevens	geen gegevens
Caroline Yarbrough	Chief Commercial Officer	2yrs	geen gegevens	geen gegevens
Lynn Bodarky	Chief Business Officer	less than a year	geen gegevens	geen gegevens
J. Simeon	Executive Director of Quality Assurance	8.2yrs	geen gegevens	geen gegevens
Madhuri Vusirikala	Vice President of Clinical Development BMT & Cellular Therapy	no data	geen gegevens	geen gegevens

3.2yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ATNM wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sandesh Seth	Chairman & CEO	12.7yrs	US$4.70m	0.017% $ 7.9k
Richard Steinhart	Independent Director	11yrs	US$313.00k	0.0010% $ 463.2
David Scheinberg	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Hagop M. Kantarjian	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Richard Wahl	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Ajit S. Shetty	Independent Director	7.7yrs	US$308.50k	0.0024% $ 1.1k
C. Nicholson	Lead Independent Director	16.8yrs	US$313.00k	0.0011% $ 490.7
Joseph Jurcic	Chairman of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Elihu Estey	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
John Pagel	Chairman of Scientific Advisory Board & Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Alexander Perl	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Sergio Giralt	Member of Scientific Advisory Board	10.4yrs	geen gegevens	geen gegevens

11.0yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ATNM zijn ervaren en ervaren (gemiddelde ambtstermijn van 11 jaar).

Actinium Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 27, 2024

Actinium Pharmaceuticals, Inc. Appoints June Almenoff to its Board

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 30, 2023

Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer

Actinium Pharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022

Insufficient new directors

Recent updates

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 27, 2024

Actinium Pharmaceuticals, Inc. Appoints June Almenoff to its Board

Price target decreased by 18% to US$19.56

No longer forecast to breakeven

Actinium Pharmaceuticals, Inc. Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S

Actinium Pharmaceuticals, Inc. Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease

Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell Small Cap Comp Value Index

Actinium Pharmaceuticals, Inc. Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in Tp53 Positive Patients At the Eha 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 Sierra Trial

Actinium Pharmaceuticals, Inc. Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern

Forecast breakeven date pushed back to 2026

Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy

Price target increased by 8.4% to US$25.36

Price target increased by 32% to US$23.40

Actinium Pharmaceuticals, Inc. Announces Results from the Phase 3 SIERRA Trial of Iomab-B Were Presents in an Oral Presentation At the 65th Annual American Society of Hematology Meeting & Exposition

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 30, 2023

Consensus revenue estimates fall by 85%

Price target decreased by 25% to US$18.61

Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer

Actinium Pharmaceuticals, Inc. Announces Oral Presentation at ASH Annual Meeting

National Institutes of Health Awards Actinium A Small Business Technology Transfer Grant Extension to Actinium Pharmaceuticals, Inc

Price target decreased by 13% to US$24.78

Consensus EPS estimates fall by 10%

Price target decreased by 8.9% to US$27.41

Consensus revenue estimates decrease by 52%, EPS upgraded

Consensus revenue estimates increase by 13%

Price target increased by 15% to US$32.62

Actinium Pharmaceuticals, Inc. to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings

Forecast to breakeven in 2025

Actinium Highlights Survival Data in Relapsed/Refractory Aml Patients with Prior Venetoclax Treatment And/Or with A Tp53 Mutation from the Actimab-A Clag-M Combination Trial Oral Presentation At Ash

Consensus revenue estimates fall by 16%

Actinium Pharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022

Consensus forecasts updated

Forecast to breakeven in 2024

Price target increased to US$28.43

Insufficient new directors

Actinium Pharmaceuticals, Inc. Provides Update on Iomab-B and the Pivotal Phase 3 Trial

Price target increased to US$27.23

Actinium Pharmaceuticals, Inc. Announces Positive Top-Line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. Announces Executive Changes

Actinium Pharmaceuticals, Inc. Announces Executive Appointments

Actinium Pharmaceuticals, Inc. Provides Topline Results for the Pivotal Phase 3 Sierra Trial for Iomab-B

No longer forecast to breakeven

Price target decreased to US$24.04

Consensus revenue estimates fall by 22%

Consensus forecasts updated

Consensus revenue estimates increase by 193%

Price target decreased to US$26.71

Insufficient new directors

Actinium Pharmaceuticals, Inc. Highlights Data from Full Patient Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B Was Presented in an Oral Presentation At the Upcoming Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR

Actinium Pharmaceuticals, Inc. Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR

Forecast to breakeven in 2024

Forecast to breakeven in 2023

Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with Clag-M for Patients with Relapsed or Refractory AML

Actinium Pharmaceuticals, Inc. Announces Positive Data from Fully Enrolled Pivotal Phase 3 SIERRA Trial of Iomab-B Presents at 63rd American Society of Hematology Annual Meeting and Exposition

Forecast to breakeven in 2023

Chief Medical Officer Mark Berger has left the company

Chief Medical Officer Mark Berger has left the company

Actinium Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B

Consensus forecasts updated

Price target decreased to US$35.00

Actinium Pharmaceuticals, Inc. Announces Safety Data from Phase 3 SIERRA Trial of Iomab-B

Actinium Pharmaceuticals, Inc. Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual Meeting

Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC

New 90-day low: US$7.75

Actinium Pharmaceuticals, Inc. Appoints Mark Kubik as Chief Business Officer

Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies